MSD
Contact UsWorldwide
   
Home Products Research About MSD
E-mail updates
לתמיכה טכנית




Articles provided on this Web site or that are linked to from this website are owned by third parties and protected by copyright laws. Authorized users have permission to download, display, view, and print a single copy for their personal use for research and private study purposes. Any other use is prohibited unless permission is obtained from the copyright owner. Authorized users may not remove, alter, or modify any part of the article, including the authors' names and copyright notices.

NEWSLETTERS

The Symposium: E coli — Is This the Real Killer Pathogen?
Patient Case Discussion About Treatment Options

PM Hawkey

View Article
 
Role of Ertapenem in the Era of Antimicrobial Resistance
Carmeli Y
  View Article   
Unmasking antibacterial resistance
recent developments, clinical impact and possible solutions

Chan C
  View Article   
RECENT ARTICLES
"Collateral damage" from cephalosporin or quinolone antibiotic therapy
Paterson DL Clin Infect Dis 2004 May 15;38 Suppl 4:S341–5345.
  View Article   
CTX-M: Changing the face of ESBLs in the UK
Livermore DM, Hawkey PM J Antimicrob Chemother 2005 Sep;56(3):451–454.
  View Article   
Minimising antibiotic resistance
Livermore DM J Lancet 2005 Jul;5(7):450–459.
  View Article   
Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: Observations from two randomized comparative clinical trials of ertapenem therapy
DiNubile MJ et al Eur J Clin Microbiol Infect Dis 2005 Jul;24(7):443–449.
  View Article   
Ertapenem: The first group 1 carbapenem
Acuna C Drugs Today 2005 May;41[suppl A]:1–16.
  View Article   
Ertapenem: review of a new carbapenem
Zhanel GG Expert Rev Anti Infect Ther 2005;3(1):23–39.
  View Article   
Ertapenem versus ceftriaxone and metronidazole as treatment for complicated intra-abdominal infections
Navarro NS et al International Journal of Surgery 2005;3:24–34.
  View Article   
PRIMARY STUDY RESULTS
Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): Prospective, randomised, controlled, double-blinded, multicentre trial
Lipsky BL, Armstrong AG, Citron DM et al J Lancet 2005 Nov 12;366:1695–1703.
  View Article   
Ertapenem, the first of a new group of carbapenems
Shah PM, Isaacs RD J Antimicrob Chemother 2003;52(4):538–542.
  View Article   
Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults
Yellin AE, Hassett JM, Fernandez A et al Int J Antimicrob Agents 2002;20(3):165–173.
  View Article   
 
PrintPrintable Version

MSD- Merck Sharp & Dohme, Israel